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Tricuspid Regurgitation in Mitral Valve Disease
Incidence, Prognostic Implications, Mechanism, and Management
Avinoam Shiran, MD,* Alex Sagie, MD†‡
Haifa, Petah Tikva, and Ramat Aviv, Israel
Tricuspid regurgitation (TR) in patients with mitral valve (MV) disease is associated with poor outcome and pre-
dicts poor survival, heart failure, and reduced functional capacity. It is common if left untreated after MV re-
placement mainly in rheumatic patients, but it is also common in patients with ischemic mitral regurgitation. It
is less common, however, in those with degenerative mitral regurgitation. It might appear many years after sur-
gery and might not resolve after correcting the MV lesion. Late TR might be caused by prosthetic valve dysfunc-
tion, left heart disease, right ventricular (RV) dysfunction and dilation, persistent pulmonary hypertension,
chronic atrial fibrillation, or by organic (mainly rheumatic) tricuspid valve disease. Most commonly, late TR is
functional and isolated, secondary to tricuspid annular dilation. Outcome of isolated tricuspid valve surgery is
poor, because RV dysfunction has already occurred at that point in many patients. MV surgery or balloon valvot-
omy should be performed before RV dysfunction, severe TR, or advanced heart failure has occurred. Tricuspid
annuloplasty with a ring should be performed at the initial MV surgery, and the tricuspid annulus diameter (3.5
cm) is the best criterion for performing the annuloplasty. In this article we will review the current data available
for understanding the prognostic implications, mechanism, and management of TR in patients with MV
disease. (J Am Coll Cardiol 2009;53:401–8) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.048b
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m74-year-old man is admitted to the hospital for the
reatment of exacerbation of congestive heart failure from
hich he has suffered for the last 2 years. He has rheumatic
eart disease and had mitral valve replacement (MVR) with
mechanical bileaflet prosthetic valve for predominantly
itral regurgitation (MR) 12 years before his admission. At
hat time he had good left ventricular (LV) contraction, his
ulmonary artery pressure was 32/16 mm Hg, and he had
o clinical tricuspid regurgitation (TR). He is in chronic
trial fibrillation (AF), his neck veins are distended with
rominent V waves, and he has an enlarged pulsating liver
nd severe peripheral edema. Echocardiography reveals a
ormally functioning prosthetic mitral valve (MV), good
V contraction, and no aortic valve disease. The right
entricle (RV) and right atrium are dilated and RV function
s reduced. The tricuspid valve (TV) leaflets appear normal,
ut the tricuspid annulus (TA) is dilated and measures 4.5
m, and there is severe malcoaptation of the TV leaflets and
evere TR (Fig. 1, Online Videos 1 and 2).
he clinical problem. The preceding case illustrates the
roblem of TR in patients with MV disease. Management
f such patients is challenging and difficult at such a stage
rom the *Department of Cardiovascular Medicine, Lady Davis Carmel Medical
enter and the Ruth and Bruce Rappaport Faculty of Medicine, Technion–Israel
nstitute of Technology, Haifa, Israel; †Department of Cardiology, Rabin Medical
enter, Petah Tikva, Israel; and the ‡Sackler Faculty of Medicine, Tel Aviv
niversity, Ramat Aviv, Israel.a
Manuscript received May 28, 2008; revised manuscript received August 12, 2008,
ccepted September 15, 2008.ecause of advanced RV dysfunction and failure. The best
reatment is in fact prevention at an earlier stage and
equires understanding the mechanism, natural history, and
onsequence of TR in patients with MV disease, which is
he focus of this review. Since the problem of late TR was
eviewed by Groves et al. in 1992 (1), new data have become
vailable. Unfortunately, randomized prospective trials to
uide the management of such patients are lacking, as they
re in other areas in valvular heart disease.
Patients who have severe TR at the time of MV surgery
hould obviously have their TV repaired at the time of the
nitial MV surgery (2,3). In patients with less than severe
R, however, TR might progress after surgery if the TV is
eft untreated. Matsuyama et al. (4) reported significant TR
at least grade 3) on echocardiography performed late after
VR in 37% of the patients with grade 2 TR before
urgery.
In this review, we will summarize the new available data
ccumulated regarding TR in patients with MV disease
ith emphasis on the best criteria for concomitant TV
epair in patients undergoing MV surgery.
ncidence of TR inMV disease. Tricuspid regurgitation is
requently present in patients with MV disease, and more
han one-third of the patients with mitral stenosis have at
east moderate TR (5,6). Clinically severe TR has been
eported in 23% to 37% of patients after MVR for rheu-
atic heart disease (7,8). In 14%, TR occurred in thebsence of significant left heart disease, pulmonary hyper-
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Tricuspid Regurgitation in MV Disease February 3, 2009:401–8tension, or obvious organic TV
disease (7). The incidence of
echocardiographically moderate
or severe late TR in rheumatic
patients is even higher (68%) (8).
In most cases TR is diagnosed
late after MVR, 10 years on av-
erage, but can appear as late as 24
years after the initial surgery
(7,8).
Although late TR has most
often been reported in patients
with rheumatic heart disease, it is
not confined to rheumatic pa-
tients (9,10). Moderate or severe
TR was reported in as many as
74% of patients 3 years after sur-
ical repair of ischemic MR (10). De Bonis et al. (11) reported
4% grade 3 or more TR in patients who had surgery for
unctional MR secondary to dilated cardiomyopathy (70%
schemic and 30% nonischemic), and those patients had
oncomitant TV repair. Grade 3 or more TR was still present
n 22% of the patients 3.5 years after surgery. Dreyfus et al. (9)
eported 34% late TR (grade 3 or 4) in a group of 163 patients
ith a mixed etiology for MR who were followed for 5 years
fter MV repair. The most common etiology in this group was
egenerative (Barlow’s disease in 38%, dystrophic in 27%),
ollowed by ischemic in 13% and rheumatic in only 11%.
ricuspid regurgitation is probably less frequent in patients
ith MR secondary to MV prolapse. Koukoui et al. (12)
eported moderate or severe TR in 15% of patients with MV
Abbreviations
and Acronyms
AF  atrial fibrillation
LV  left
ventricle/ventricular
MR  mitral regurgitation
MV  mitral valve
MVR  mitral valve
replacement
RV  right
ventricle/ventricular
TA  tricuspid annulus
TR  tricuspid
regurgitation
TV  tricuspid valve
A
RV
RA
Figure 1 Patient With Late Tricuspid Regurgitation After Mitral
(A) Apical 4-chamber view showing right ventricle (RV) and tricuspid annulus dilatio
of tricuspid valve leaflets during systole (arrow) (Online Video 1). (B) Color flow Dopplerrolapse and at least moderate MR (n  477). Tricuspid
egurgitation progressed in 14% of the patients during a mean
ollow-up of 4 years. Late TR is probably less of a problem
n MV prolapse, but more data and longer follow-up are
eeded (13).
rognostic implications of TR in patients with MV
isease. Patients with mitral stenosis and moderate or
evere TR before MVR are more likely to have class III or
V heart failure after a mean follow-up of 8 years compared
ith patients with mild TR (56% vs. 14%) (6). Tricuspid
egurgitation after MVR predicts poor outcome. Ruel et
l. (14) reported the risk factors for heart failure and
eath in 708 patients after MVR. Moderate-to-severe
R on echocardiography during follow-up was an inde-
endent predictor of New York Heart Association func-
ional class III or IV heart failure, heart failure-related
eath, and even all-cause mortality during the 5 years of
ollow-up. Only 77% of the patients in this study,
owever, had follow-up echocardiography.
In a smaller study (n  42), Henein et al. (15) reported
5-year survival of only 50% in rheumatic patients with
linical and echocardiographic severe TR after MV surgery,
ompared with no deaths in patients with mild TR.
Significant TR requiring TV surgery predicts poor sur-
ival in patients undergoing valve surgery (16,17). Tricuspid
egurgitation is also a predictor of poor outcome in patients
ndergoing balloon mitral valvotomy for mitral stenosis.
atients with pre-procedural severe TR have more severe
V disease, higher pulmonary vascular resistance, a smaller
ncrease in MV area after valvotomy, as well as poorer
e Replacement
uspid annulus diameter 4.5 cm) with severe malcoaptationB
Valv
n (tric
showing severe tricuspid regurgitation (Online Video 2). RA  right atrium.
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February 3, 2009:401–8 Tricuspid Regurgitation in MV Diseaseutcome: lower overall survival, more heart failure, and need
or repeat valvotomy or MVR (Fig. 2) (18).
Patients with TR after MVR have reduced exercise
apacity compared with patients without TR. Groves et al.
19) have shown that patients with isolated severe TR after
VR have reduced exercise duration, maximal oxygen
onsumption, and anaerobic threshold compared with pa-
ients without TR, despite having good LV and prosthetic
alve function.
Patients with severe TR after MVR undergoing isolated TV
urgery usually have a poor outcome with high perioperative
Figure 2 Event-Free Survival After Balloon
Mitral Valvotomy by TR Severity
Events were defined as death, New York Heart Association functional class III
or IV, MV surgery, or repeat mitral valve balloon valvotomy (n  318). Patients
with severe tricuspid regurgitation (TR) had significantly worse event-free sur-
vival compared with patients with mild TR. Reprinted, with permission, from
Sagie et al. (18).
Figure 3 Pathogenesis of Tricuspid Regurgitation in Mitral Valv
DCM  dilated cardiomyopathy; MR  mitral regurgitation; MS  mitral stenosis;ortality, poor late survival, and no significant improvement in
unctional capacity in many of them (20–23). Perioperative
ortality might reach 50%, but it was usually reported between
1% and 20% (13,20,23,24). Mangoni et al. (20) reported 20%
perative mortality and 1.2 years’ median survival in 15
atients, most of them rheumatic, undergoing isolated TV
eplacement. One-half of the surviving patients were in New
ork Heart Association functional class III or IV. The results
ight be better for patients with preserved RV function
eferred early for surgery (23), but data regarding the outcome
f such an approach and the optimal timing for surgery in such
atients is lacking.
athogenesis of TR in MV disease. The pathogenesis of
R in MV disease is complex and multifactorial (Fig. 3).
ost often TR is functional, secondary to RV dilation and
ysfunction and tricuspid annular dilation. Mitral valve
isease (usually rheumatic or ischemic) leads to mitral
tenosis or regurgitation, which in turn leads to increased
eft atrial pressure and, if severe enough, to secondary
ulmonary hypertension. Long-standing pulmonary hyper-
ension might lead to RV dysfunction and remodeling,
hich leads to TA dilation, papillary muscle displacement,
nd tethering of the TV leaflets, leading to TR (25–29).
ricuspid regurgitation itself leads to further RV dilation
nd dysfunction, more TV annular dilation and tethering,
nd worsening TR. With increasing TR the RV dilates and
ventually fails, causing increased RV diastolic pressure and
shift of the interventricular septum toward the LV.
ecause of ventricular interdependence, this might com-
ress the LV, causing restricted LV filling and increased LV
iastolic and pulmonary artery pressure. This phenomenon
ease
rheumatic heart disease; RV  right ventricle; TV  tricuspid valve.e Dis
RHD 
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Tricuspid Regurgitation in MV Disease February 3, 2009:401–8as named “restriction dilation syndrome” by Antunes and
arlow (13).
Increased left atrial size and pressure might also cause
F, which in turn causes right atrial dilation leading to
urther tricuspid annular dilation. Atrial fibrillation has been
ecognized as an important risk factor for the development
f TR in patients with MV disease as well as for the
ersistence or occurrence of TR after MV surgery or balloon
itral valvotomy (4,30,31). Furthermore, patients who have
concomitant successful Maze procedure during their MV
urgery were reported to have significantly less TR at
ollow-up (32).
In patients with rheumatic valve disease, organic TV
nvolvement might also cause TR. Tricuspid valve leaflet
hickening and restriction had been reported in about
ne-third of the patients with moderate or severe TR after
VR, but the true incidence of organic TV involvement
ight be higher (8). With transesophageal echocardiogra-
hy and 3-dimensional reconstruction, Henein et al. (15)
ound more subtle organic TV involvement in 12 of 15
atients with isolated severe TR who had MVR for rheu-
atic heart disease. Scarring, leaflet thickening, and even
ome chordal shortening are routinely found when resected
Vs from patients with functional TR are carefully exam-
ned (33). These findings, unfortunately, are nonspecific for
heumatic valvular changes and are frequently found in
atients with TR and severe RV hypertension secondary to
ongenital heart disease (33).
In many patients with severe pulmonary hypertension,
ulmonary pressure regresses after successful MVR or bal-
oon valvotomy (34–36). The immediate decrease in pul-
onary artery pressure is due to the elimination of the
assive component of pulmonary hypertension. It depends
n effective lowering of left atrial pressure, which might be
indered by prosthesis-patient mismatch, suboptimal relief
f mitral stenosis by balloon valvotomy, or significant MR
35–37). A progressive decline in reactive pulmonary arte-
iolar vasoconstriction might further decrease pulmonary
esistance over a period of 1 week to several months,
specially in younger patients with less chronic disease
35,38–40). An irreversible component, caused by pulmo-
ary arteriolar medial hypertrophy, might cause persistent
r recurrent pulmonary hypertension (36).
Although pulmonary hypertension is important in the
athogenesis of late TR, it might be normal before MVR
19). Porter et al. (8) reported that pre-operative pulmonary
rtery pressure did not predict late TR. Kaul et al. (41), in
n elegant study, reported the outcome of 86 rheumatic
atients with moderate functional TR undergoing MVR.
hey found that, compared with patients with nonsevere
ulmonary hypertension (systolic pulmonary artery pressure
1  6 mm Hg), patients with severe pulmonary hyperten-
ion (78  14 mm Hg) had far less late TR at follow-up,
etter functional capacity, and significantly better survival.
he probable reason for this surprising finding was that
atients with nonsevere pulmonary hypertension had worseV function. Right ventricular function is an important
eterminant of outcome in patients with MV disease and
R (23,42). An alternative explanation is that patients with
onsevere pulmonary hypertension were more likely to have
rganic TR.
Tricuspid annular dilation is probably the most important
actor in the development of late TR, and it is also the target
or intervention. The normal TA is saddle-shaped, with the
ighest points located in an anteroposterior orientation and
he lowest points in a mediolateral orientation. With the
evelopment of functional TR, the TA becomes dilated and
ore planar and circular (43,44). Antunes and Barlow (13)
uggested that in rheumatic patients direct involvement of
he TA by the rheumatic process might weaken the annulus
nd cause it to dilate. The normal TA diameter, as mea-
ured by echocardiography in the 4-chamber view between
he base of the septal and the base of the lateral TV leaflets,
s 2.8  0.5 cm (28). Sugimoto et al. (27) reported a good
orrelation between TA diameter and TR regurgitant vol-
me (Fig. 4). In addition, annular dilation and not pulmo-
ary hypertension, RV dilation, or tricuspid tenting is the
est determinant of functional TR (28). Reduced tricuspid
nnular shortening, encountered in patients with severe
ricuspid annular dilation and RV dysfunction, also deter-
ines TR severity (26,45). Interestingly, in patients with
hronic pulmonary thromboembolic hypertension in whom
R resolved after pulmonary thromboendarterectomy and
n patients who had successful mitral balloon valvotomy,
here was no change in TA diameter after resolution of
ulmonary hypertension (31,46). This implies that TA
ilation might be irreversible and might explain the mech-
nism of late TR in MV disease.
Figure 4 Correlation Between TAD and VTR
There is good correlation in both patients with valvular heart disease (VHD)
(r  0.87) and patients with atrial septal defect (ASD) (r  0.88). The correla-
tion lines cross the x-axis at a tricuspid annulus diameter (TAD) value of 33 to
34 mm, which is the threshold for tricuspid regurgitation. Reprinted, with per-
mission, from Sugimoto et al. (27). VTR  tricuspid regurgitant volume.
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February 3, 2009:401–8 Tricuspid Regurgitation in MV DiseaseAlthough late TR after MVR is often isolated and occurs
n the absence of significant left heart disease, it is important
o look for a dysfunctional prosthetic MV (paravalvular leak
r stuck leaflet) by transesophageal echocardiography in
atients presenting with severe TR late after MVR (47).
oes TR resolve after correcting the MV lesion? Lessons
rom patients undergoing balloon mitral valvotomy or
VR. In an early report by Braunwald et al. (33) it was
uggested that TR resolves after MVR and there is no need
or concomitant TV surgery. Lowering pulmonary artery
ressure might eliminate severe functional TR. Severe TR
esolved in 70% of the patients with chronic pulmonary
hromboembolic hypertension who were examined early
fter pulmonary thromboendarterectomy (46). Later, it
ecame apparent that TR might not resolve after MV
urgery, might become clinically apparent more than 20
ears after the surgery, and is fairly common (8,45,48,49). In
atients undergoing balloon mitral valvotomy for mitral
tenosis, the true natural history of concomitant TR can be
etermined, because the TV is left untreated. Tricuspid
egurgitation did not improve in 49% to 80% of the patients
ith moderate or severe TR after successful mitral balloon
alvulotomy (30,50). Tricuspid regurgitation was more
ikely to improve in patients with the following character-
stics: 1) younger age; 2) functional (as opposed to organic)
R; 3) smaller MV area; 4) severe pulmonary hypertension;
) larger resolution of pulmonary hypertension after valvot-
my; and 6) no AF (30). Song et al. (31) compared mitral
alvotomy and surgical treatment (MV surgery and TV
epair) in 92 patients with mitral stenosis and severe TR.
lthough event-free survival was not different in this
elatively small retrospective study, patients in the surgical
roup were older and had more AF and a higher MV score.
vent-free survival at 7 years, however, was significantly
etter in the subgroup of patients with AF who had surgery
ompared with those with AF who had valvotomy without
V repair, mainly due to heart failure events secondary to
R in the valvotomy group. Furthermore, 98% of the
atients in the surgical group were free of grade 2 TR,
ompared with 46% of the patients who had balloon
alvotomy.
The resolution of TR reported by Braunwald et al. (33) in
heir early study might be explained by the fact that their
atients were relatively young, with good RV function as
videnced by high systolic pulmonary artery pressure (aver-
ge 75 mm Hg) and relatively low right atrial pressure
average 11 mm Hg). Furthermore, the follow-up in this
tudy was short (30 months on average), whereas TR might
ppear many years after MVR.
anagement of TR in MV disease. Importance of
oncomitant tricuspid annuloplasty at the time of initial
V surgery. Because late TR in MV disease is usually due
o TA dilation (although rheumatic patients might have
rganic leaflet disease as well) and carries significant mor-
idity and mortality, and because the results of repeat
urgery for isolated late TR are poor (20,22,24), concomi- “ant TV repair with an annuloplasty ring should be per-
ormed at the time of the initial MV surgery. Tricuspid
alve annuloplasty adds little time and complexity to MV
urgery and results in very few complications (9,51,52). In
atients with non-severe organic TV disease, TV repair is
robably better than replacement (51). Bioprosthetic valves
egenerate with time, and mechanical valves in the tricuspid
osition tend to thrombose (53). Singh et al. (51) reported
5-fold risk of early death during the perioperative period
ith TV replacement compared with TV repair, and in their
tudy TV replacement was an independent predictor of poor
urvival after surgery. In some patients with severe organic
eaflet involvement, TV repair might not be possible and the
alve should be replaced to avoid recurrent severe TR or TS,
ut with less severe leaflet disease suboptimal results with
ild residual TR might be well tolerated (in contrast to MV
epair, where suboptimal initial results are usually not
ccepted) (13).
Tricuspid valve repair with an annuloplasty ring resulted
n significantly improved long-term survival (15 years),
vent-free survival, and survival free of recurrent TR com-
ared with De Vega suture annuloplasty in the study
eported by Tang et al. (52). Tricuspid valve ring annulo-
lasty was also an independent predictor of long-term
urvival in that study. The durability of TV repair was
ssessed by McCarthy et al. (54). All TV repair techniques
ad an immediate failure rate (grade 3 TR or more) of
pproximately 14%. Whereas patients who had a ring
nnuloplasty with a semi-rigid ring (Carpentier-Edwards)
ad no progression of TR, more than 30% of the patients
ho had a De Vega procedure had significant TR after 8
ears (54). Some surgeons report good results with a
odified De Vega repair with pledgeted sutures in patients
ith nonsevere organic TV involvement (13).
The best evidence for the utility of TV ring annuloplasty
uring MV surgery and the importance of TA diameter as
criterion for TV repair comes from the study of Dreyfus et
l. (9). They studied 311 patients undergoing MV repair
65% degenerative and only 14% rheumatic MV disease).
he TV annulus diameter was measured intraoperatively
ith a ruler, from the anteroseptal commissure to the
nteroposterior commissure. The TV repair with a
arpentier-Edwards ring was performed regardless of the
egree of TR, if the TA diameter was 7 cm (equivalent to
cm by echocardiography [A. Berrebi, personal communi-
ation, November 2006]). Tricuspid valve repair was per-
ormed in 48% of the patients, despite the fact that 88% had
rade 1 TR. Although the patients who had TV repair
ere sicker, they tended to have better survival (90.3% vs.
5.5% at 10 years, p  NS) and had significantly less TR
0.7% vs. 34% grade 3 or 4 TR, p  0.01) and better
unctional capacity at follow-up (0% vs. 14% functional
apacity 3 or 4, p 0.001). These results imply that the TA
iameter threshold for repair should have been lower,
omewhere between 3.0 and 4.0 cm. Perhaps it is best to
freeze” the normal TA at 3.0 cm. Groves et al. (1)
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Tricuspid Regurgitation in MV Disease February 3, 2009:401–8uggested a threshold of 2.1 cm/m2 (equivalent to 3.6 cm for
n average person). They relied on a study by Chopra et al.
55), who found this diameter to best differentiate severe
rom nonsevere TR. In their study the authors did not
ttempt, however, to predict late TR. The threshold should
robably be lower with increasing degrees of TR and in
heumatic patients. Prospective, randomized trials are
eeded to better define this cutoff point. On the basis of the
vailable information and personal experience, we believe
hat prophylactic TV repair should be performed in patients
ndergoing MVR regardless of TR severity whenever the
V annulus is 3.5 cm, especially in rheumatic TR.
We believe that this approach is appropriate for patients
ith ischemic MR and also for patients with functional MR
econdary to dilated cardiomyopathy (ischemic and non-
schemic). Radovanovic et al. (56,57) reported good results
ith systematic MV and TV annuloplasty in relatively
oung patients (mean age 50 to 55 years) with ischemic and
onischemic dilated cardiomyopathy, but his studies were
onrandomized. Early TV repair before the occurrence of
rreversible RV dysfunction is probably also appropriate in
atients with isolated TR secondary to TA dilation without
eft-sided heart disease (58).
Treatment of patients who develop late isolated TR after
VR like the patient we described is difficult (2,3). Ag-
ressive antifailure therapy with loop diuretic drugs and
pironolactone is the mainstay of therapy and might retard
R progression. In some patients in whom surgery is no
onger an option, chronic dialysis might prove useful, in our
xperience, in treating volume overload and improving life
uality. Early on, when patients have relatively few symp-
oms, the high-risk surgery might seem unjustified. Later,
hen symptoms justify surgery, RV dysfunction might
lready be irreversible. Right ventricular function is still hard
o measure by conventional echocardiography. Recently,
issue Doppler imaging was found to be helpful in identi-
ying patients with preserved RV function (tricuspid systolic
nnular velocity 9.5 cm/s) (23). Newer techniques such as
-dimensional echocardiography, magnetic resonance im-
ging, and Doppler indexes such as the RV myocardial
erformance index (MPI) and isovolumic acceleration index
IVA) might prove useful in the future to better assess RV
unction and might help to find the ideal timing of surgery
o avoid irreversible RV dysfunction (59).
urrent guidelines for TV repair and replacement. Both
he American College of Cardiology/American Heart As-
ociation and the European Society of Cardiology (ESC)
uidelines give a class I recommendation for TV repair in
atients with severe TR undergoing MV surgery (2,3). The
SC guidelines give a class IIa recommendation for con-
omitant TV repair in patients with a TA diameter 40
m or moderate TR, whereas the American College of
ardiology/American Heart Association gives a more vague,
lass IIb recommendation for patients with less than severe
R. The ESC also gives a class IIa recommendation for TVepair in patients with symptomatic, isolated TR late after
eft-sided valve surgery, in the absence of left-sided myo-
ardial or RV dysfunction and without severe pulmonary
ypertension. On the basis of the current review, we agree
ore with the European view and support a more aggressive
pproach toward TV repair. Surgical intervention is not
ndicated in asymptomatic patients with severe TR devel-
ping RV dysfunction, in contrast to asymptomatic patients
ith severe MR or AR, in whom there is a clear and strong
ndication for surgical intervention when even mild LV
ysfunction is present. Therefore, many patients with severe
R are referred for TV surgery too late, when RV dysfunc-
ion has already occurred and in a poor functional class. This
ight explain the poor surgical results in many of them.
ecommendations. Detailed TV assessment, including
easurement of the TA diameter, is mandatory in patients
ith MV disease. Mitral valve surgery or balloon valvotomy
hould be performed before RV dysfunction, severe TR, or
dvanced heart failure has occurred. This is similar to the
urrent approach of performing MV repair before the
ccurrence of LV dysfunction or closing an atrial septal
efect before the occurrence of RV dysfunction.
A TV annuloplasty with a ring is the best procedure to
orrect or prevent TR in most cases. It improves survival,
revents late TR and heart failure, and should therefore be
erformed at the time of the initial MV surgery. The TA
iameter is the best guide to select patients for TV repair,
nd the echocardiographic cutoff should be somewhere
round 3.5 cm regardless of TR severity and might be lower
or rheumatic patients. Patients with significant TR who are
lder and have longstanding MV disease, AF, nonsevere
ulmonary hypertension, and organic TV disease will ben-
fit more from MV surgery and TV repair/replacement than
rom percutaneous balloon valvotomy.
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irector, Echocardiography, Department of Cardiovascular Med-
cine, Lady Davis Carmel Medical Center, 7 Michal Street, Haifa
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